Benefit and Risk of Anticoagulation

Oral Direct Thrombin Inhibition With Ximelagatran

Jonathan L. Halperin, MD

The Zena and Michael A. Wiener
Cardiovascular Institute
Mount Sinai Medical Center
New York, NY

Ximelagatran

Basis for Proposed Clinical Indications

Indication	Dose (bid)	Comparator	Pivotal studies
Long-term secondary prevention of VTE	24 mg	Placebo	THRIVE III
Prevention of VTE after knee replacement	36 mg	Warfarin	EXULT A & B
Prevention of stroke in atrial fibrillation	36 mg	Warfarin	SPORTIF III & V

Cumulative Risk of ALT > 3 × ULN

Non-surgical Long-term Safety Population



Local and central laboratory data.

Net Risk/Benefit of Ximelagatran

Long-term Secondary Prevention VTE

Primary Events + Major Bleeding + Death



Schulman S, et al. *N Engl J Med.* 2003;349:1713.

Net Risk/Benefit of Ximelagatran

Prevention VTE After Knee Replacement

Primary Events + Major Bleeding + Death



Francis CW, et al. *N Engl J Med.* 2003;349:1703-1712.
Colwell CW, et al. *J Bone Joint Surg Am.* In press.

Stroke and Systemic Embolism

High-risk Patients in Earlier Studies



Hart RG, Halperin JL, et al. *Ann Intern Med.* 2003;138:831.

The SPORTIF Trials

Pooled Analysis (ITT)



Halperin JL and the SPORTIF-V Investigators. *Circulation.* 2003;108:2723.

Net Risk/Benefit of Ximelagatran

Prevention Stroke in Atrial Fibrillation

Primary Events + Major Bleeding + Death



Halperin JL and the SPORTIF-V Investigators. *Circulation.* 2003;108:2723.

Atrial Fibrillation Population

Projections (USA)



Go AS, et al. *JAMA.* 2001;285:2370.

Warfarin for Atrial Fibrillation

Anticoagulation in Primary Care Practice



Samsa GP, et al. *Arch Intern Med.* 2000;160:967.

Jonathan L. Halperin, MD

The Zena and Michael A. Wiener
Cardiovascular Institute
Mount Sinai Medical Center
New York, NY